Estradiol Undecylate: Definition, Prescribing, and Availability
Estradiol undecylate is a long-acting injectable estrogen ester that is NOT available in the United States and has extremely limited use globally, with essentially no role in modern clinical practice.
What is Estradiol Undecylate?
Estradiol undecylate is an esterified form of estradiol designed for intramuscular injection with an extended depot effect. Historical research from the 1970s-1980s evaluated its pharmacokinetics and clinical applications, but it never gained widespread adoption 1, 2.
The compound was studied primarily in two contexts:
- Postmenopausal hormone therapy - where it was compared to other estradiol esters for depot effect 2
- Prostate cancer treatment - where it was used as androgen suppression therapy in men with advanced disease 1
Geographic Availability
This medication is not available in the United States and is not mentioned in current FDA-approved estrogen formulations 3. The 2015 Endocrine Society guidelines make no reference to estradiol undecylate in their comprehensive review of estrogen preparations 4.
The only contemporary reference suggests it may have been used "outside the United States" historically, similar to promestriene (estradiol diether), but even that agent is noted to have "limited evidence" 4.
Historical Prescribing Information
Based on limited historical data:
- Dosing: 100 mg intramuscularly per month was used in prostate cancer treatment 1
- Route: Intramuscular injection only
- Depot effect: Designed for extended release, though specific duration data is limited 2
Current Clinical Relevance
Estradiol undecylate has no place in modern clinical practice. Current evidence-based guidelines recommend:
For Menopausal Hormone Therapy:
- Oral estradiol tablets: Starting doses of 0.5-2 mg daily 4
- Transdermal estradiol: Patches, gels, or sprays (preferred for VTE risk reduction) 4
- Vaginal estradiol: Low-dose (10 µg tablets) for genitourinary symptoms 4
For Injectable Estrogen (When Preferred):
Modern practice uses estradiol valerate or estradiol cypionate, not undecylate:
- Starting dose: ≤5 mg weekly (subcutaneous or intramuscular) 5
- Target levels: 100-200 pg/mL, though this range is increasingly questioned 6, 7
- Recent data suggests current guideline doses are too high and lead to supraphysiologic levels 7, 5
Key Clinical Pitfall
Do not attempt to prescribe or source estradiol undecylate. If a patient requests injectable estrogen therapy:
- Use FDA-approved estradiol valerate or estradiol cypionate 3
- Start at lower doses than older guidelines suggest (≤5 mg weekly) 7, 5
- Monitor estradiol levels relative to injection timing 7
- Consider subcutaneous route as equally effective as intramuscular 7
The medication's absence from all current guidelines, FDA databases, and modern literature indicates it is obsolete and has been superseded by better-studied, more readily available estrogen formulations.